Cargando…

Review of the endocrine organ–like tumor hypothesis of cancer cachexia in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal types of solid tumors, associated with a high prevalence of cachexia (~80%). PDAC-derived cachexia (PDAC-CC) is a systemic disease involving the complex interplay between the tumor and multiple organs. The endocrine organ–like tumor (E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Ying-Chun, Ahmed, Azaj, Lai, Hsueh-Chou, Cheng, Wei-Chung, Yang, Juan-Chern, Chang, Wei-Chun, Chen, Lu-Min, Shan, Yan-Shen, Ma, Wen-Lung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713001/ https://www.ncbi.nlm.nih.gov/pubmed/36465353 http://dx.doi.org/10.3389/fonc.2022.1057930

Ejemplares similares

The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
por: Wu, Yang, et al.
Publicado: (2021)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Non-coding RNAs in Pancreatic Ductal Adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes
por: Liu, Rong, et al.
Publicado: (2021)

Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma
por: Jiang, Jiahong, et al.
Publicado: (2021)

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
por: Wang, Yizhi, et al.
Publicado: (2020)

Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications
por: Angstadt, Shantel, et al.
Publicado: (2022)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
por: Zhang, Jingchang, et al.
Publicado: (2022)

Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma
por: Mitsunaga, Shuichi, et al.
Publicado: (2020)

Cachexia index as a prognostic predictor after resection of pancreatic ductal adenocarcinoma
por: Shimagaki, Tomonari, et al.
Publicado: (2023)

Pancreatic Ductal Adenocarcinoma Highly Expresses Activin A: Implications in Adipose Tissue and Cancer Cachexia
por: Xu, Pauline, et al.
Publicado: (2021)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling
por: Xu, Pauline C., et al.
Publicado: (2022)

Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
por: Zhao, Juan, et al.
Publicado: (2022)

The Role of Nonapoptotic Programmed Cell Death — Ferroptosis, Necroptosis, and Pyroptosis — in Pancreatic Ductal Adenocarcinoma Treatment
por: Hsu, Sheng-Kai, et al.
Publicado: (2022)

Vascularization, Oxygenation, and the Effect of Sunitinib Treatment in Pancreatic Ductal Adenocarcinoma Xenografts
por: Gaustad, Jon-Vidar, et al.
Publicado: (2019)

The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
por: Principe, Daniel R., et al.
Publicado: (2021)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma
por: Bao, Jingpiao, et al.
Publicado: (2022)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Development and validation of an MRI-radiomics nomogram for the prognosis of pancreatic ductal adenocarcinoma
por: Xu, Xinsen, et al.
Publicado: (2023)

The enigmatic helicase DHX9 as a candidate prognostic biomarker for resected pancreatic ductal adenocarcinoma
por: Chen, Le-gao, et al.
Publicado: (2022)

Development and validation of a nomogram to predict liver metastasis for pancreatic ductal adenocarcinoma after radical resection
por: Tong, Jingshu, et al.
Publicado: (2022)

MRI Assessment of Associations between Brown Adipose Tissue and Cachexia in Murine Pancreatic Ductal Adenocarcinoma
por: Zhang, Yaqi, et al.
Publicado: (2019)

Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma
por: Yang, Chengkun, et al.
Publicado: (2019)

Regulation of Proliferation by a Mitochondrial Potassium Channel in Pancreatic Ductal Adenocarcinoma Cells
por: Peruzzo, Roberta, et al.
Publicado: (2017)

Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma
por: Reni, Michele, et al.
Publicado: (2020)

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
por: Wang, Weijia, et al.
Publicado: (2021)

Comparison of Radiomic Features in a Diverse Cohort of Patients With Pancreatic Ductal Adenocarcinomas
por: Permuth, Jennifer B., et al.
Publicado: (2021)

Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma
por: Cao, Yingying, et al.
Publicado: (2022)

Digital quantitative tissue image analysis of hypoxia in resected pancreatic ductal adenocarcinomas
por: Siddiqui, Iram, et al.
Publicado: (2022)

Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor–resistant pancreatic ductal adenocarcinoma
por: Malvi, Parmanand, et al.
Publicado: (2022)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Loss of Cadherin-11 in pancreatic ductal adenocarcinoma alters tumor-immune microenvironment
por: Sebastian, Aimy, et al.
Publicado: (2023)

Corrigendum: Systematic characterization of the clinical relevance of KPNA4 in pancreatic ductal adenocarcinoma
por: Bao, Jingpiao, et al.
Publicado: (2023)

Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma
por: Wang, Yizhi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_goqqnfcafd76kkbp7ed4lq8g4b